FDA OKs Relistor for opioid patients

Apr 28, 2008

The U.S. Food and Drug Administration has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients receiving opioids.

The FDA said opioids are often prescribed on a continuous basis for patients with late-stage, advanced illness to help alleviate pain, such as in cases of incurable cancer, heart failure and Alzheimer's disease with dementia.

But opioids can interfere with normal bowel movements by relaxing the intestinal smooth muscles and preventing them from contracting and pushing out waste products. Relistor acts by blocking opioid entrance into the cells, thus allowing the bowels to continue to function normally.

"This new drug will be helpful to patients who experience severe constipation associated with the continuous use of morphine or other opioids, which are an important part of care for patients with late-stage, advanced illness." said Dr. Joyce Korvick, deputy director of the FDA's division of gastroenterology products.

Relistor is manufactured by Wyeth Pharmaceuticals Inc. of Philadelphia and Progenics Pharmaceuticals of Tarrytown, N.Y.

Copyright 2008 by United Press International

Explore further: FDA approves ADHD drug for binge-eating disorder

add to favorites email to friend print save as pdf

Related Stories

Galaxy dust findings confound view of early Universe

11 hours ago

What was the Universe like at the beginning of time? How did the Universe come to be the way it is today?—big questions and huge attention paid when scientists attempt answers. So was the early-universe ...

Recommended for you

Generic form of nexium approved

Jan 26, 2015

(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.